Evonik scoops CMO Leadership Award for fourth year in a row
The company wins awards in all six categories — capabilities, compatibility, expertise, quality, reliability and service
Evonik, one of the world’s largest contract development and manufacturing organizations (CDMO) for active pharmaceutical ingredients (APIs) and advanced intermediates, has been recognised as a recipient of the 2021 CMO Leadership Awards across all six categories for the fourth year running.
Winners are chosen through market research based on feedback from pharmaceutical companies that utilize outsourcing services. Evonik’s success confirms the company’s outstanding performance and value to the pharmaceutical and life science industries.
Life Science Leader magazine and Outsourced Pharma teamed up with Industry Standard Research (ISR) to assess more than 70 CMOs across 23 performance metrics as part of ISR’s 2021 Contract Manufacturing Quality Benchmarking survey of global pharmaceutical and biotechnology companies.
For the fourth consecutive year, participating companies voted for Evonik to earn awards for its capabilities, compatibility, expertise, quality, reliability and service.
As one of the world’s top CMOs for APIs and intermediates, the Health Care business line is part of the life science division Nutrition & Care and represents a key growth lever for Evonik. To meet growing customer demand for its CMO services, Evonik is expanding its production capacity at two sites in Germany, as announced in May 2020.
“To be recognized by our customers as a leader for the fourth time in a row is a tremendous honour,” said Thomas Riermeier, head of Evonik’s Health Care business line.
To address the specific needs of large or complex projects, Evonik has established a broad portfolio of advanced technologies which can be combined to support multi-step API synthesis. These technologies include continuous processes, fermentation, PEGs and mPEGs, catalysts, biocatalysts, cryogenic chemistry and polymer APIs.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance